This filing marks a fundamental shift from a cash-burning growth story to a self-funding operating model, with the cash flow inflection arriving far earlier than typical for high-growth consumer brands. The $1B General Catalyst facility removes equity dilution risk for growth funding, while the raised guidance and strong July metrics suggest accelerating momentum. Traders should watch Q3 results for confirmation of sustained positive Adjusted Free Cash Flow and monitor CAC trends as marketing spend scales further. The upcoming product launches (Hydration in Q4, Gummies in H1 2027) represent unguided upside.
Price Chart
Executive Summary
Prenetics Global (PRE) reported Q2 2026 total revenue of $46.5M (+288% YoY, +29% QoQ), with its IM8 brand contributing $45.0M (+359% YoY, +33% QoQ) at ~65% gross margin. The company raised FY2026 total revenue guidance to $220-230M and initiated FY2027 IM8 revenue guidance of $400M+. Critically, consolidated Adjusted Free Cash Flow turned positive in July 2026 for the first time, supported by a $1B non-dilutive growth financing facility from General Catalyst. This filing represents a transformative inflection point from a cash-consuming growth story to a self-funding operating model, with strong cohort economics validated by an independent third party.
Key Facts
- Q2 2026 total revenue of $46.5M, up 288% YoY (3.9x) and 29.3% QoQ.
- IM8 Q2 revenue of $45.0M, up 359% YoY (4.6x) and 33.2% QoQ, at ~65% gross margin (vs 57% a year ago).
- July 2026 was the strongest month ever: $20.9M revenue, ~$251M annualized revenue run-rate, and 47,373 new customers.
- Consolidated Adjusted Free Cash Flow turned positive in July 2026 for the first time in company history.
- Closed $1B non-dilutive growth financing from General Catalyst's Customer Value Fund on July 14, 2026.
- Raised FY2026 total revenue guidance to $220-230M (IM8: $215-222M) and initiated FY2027 IM8 revenue guidance of $400M+.
- IM8 CAC held essentially flat at ~$301 in Q2 despite nearly doubling acquisition marketing spend, then fell ~21% to ~$239 in July.
- Net loss per share improved to $(0.52) in Q2 2026 from $(0.94) a year ago, a 45% improvement.
- Completed $40M share repurchase program, with $26.9M executed in Q2.
- Independent card data from Indagari shows IM8 retaining 14.2% of customers at 20 months, outperforming AG1 (10.8%), Thorne (11.4%), and Grns (2.4%).
Financial Impact
Q2 revenue of $46.5M; FY2026 guidance raised to $220-230M; FY2027 IM8 revenue guided to $400M+; $1B non-dilutive facility closed; $40M buyback completed.
Risk Factors
- Execution risk in scaling the business while launching two new product lines (Hydration, Gummies) within 12 months.
- CAC improvement in July is preliminary and a single month does not constitute a trend; reversion could pressure unit economics.
- Youngest and largest cohorts (Q2 2026) are still immature; their long-term retention and payback remain unproven.
- Forward guidance assumes continued rapid growth; any deceleration in customer acquisition or retention would miss elevated expectations.
- Warrant overhang: ~2.36M Class C warrants at $18.00 strike could be forced-exercised if stock holds $21.60 for 10 days, adding ~$42.5M cash but also dilution.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001628280-26-057534 |
| Exhibit: ex991pressrelease.htm | 0001628280-26-057534 |
| Document: im8_q2x2026xinvestorxdec.htm | 0001628280-26-057534 |
| Document: a6-kx2026q2.htm | 0001628280-26-057534 |
| Document: 0001628280-26-057534-index-headers.html | 0001628280-26-057534 |
| Document: 0001628280-26-057534-index.html | 0001628280-26-057534 |
| Document: 0001628280-26-057534.txt | 0001628280-26-057534 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 14d ago | 6-K | $21.27 | awaiting T+60 | — | $18.37 (−13.63%) |
Sep 22, 2026 4w ago | F-1/A | $22.90 | awaiting T+60 | — | $18.37 (−19.78%) |
Aug 26, 2026 8w ago | 6-K | $25.78 | awaiting T+60 | — | $18.37 (−28.74%) |
Aug 26, 2026 8w ago | Insider Cluster | $25.78 | awaiting T+60 | — | $18.37 (−28.74%) |
Aug 26, 2026 8w ago | 3 | $25.78 | awaiting T+60 | — | $18.37 (−28.74%) |
Aug 20, 2026 9w ago | 6-K | $17.97 | awaiting T+60 | — | $18.37 (+2.23%) |
Aug 18, 2026 9w ago | 6-K | $19.40 | awaiting T+60 | — | $18.37 (−5.31%) |
Aug 18, 2026 9w ago | Press Release | $19.40 | awaiting T+60 | — | $18.37 (−5.31%) |
Aug 17, 2026 10w ago | 6-K | $19.37 | awaiting T+60 | — | $18.37 (−5.16%) |
Aug 7, 2026 11w ago | F-1/A | $18.26 | awaiting T+60 | — | $18.37 (+0.60%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers